Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong

作者：Dijing You, Jianchao Quan, David Bishai, Wwt Lam, Karen A. Grépin, Linda Chan, Dong‐Bo Wu, David Wong, William Chi Wai Wong, Jiandong Zhou · 发表于：Vaccine · 年份：2025 · DOI：10.1016/j.vaccine.2025.127625 · 被引用次数：2 · 研究领域：Cervical Cancer and HPV Research、Head and Neck Cancer Studies、Prenatal Screening and Diagnostics

BACKGROUND: Human papillomavirus (HPV) is the most common sexually transmitted infection and a leading cause of anal cancer and genital warts, particularly among men who have sex with men (MSM). In Hong Kong, HPV vaccination is currently only offered to school-aged girls, despite the high burden of HPV-related diseases among MSM, especially those living with HIV. Existing cost-effectiveness evaluations of HPV vaccination in Hong Kong primarily focus on female-only strategies and heterosexual men without accounting for differences in HPV infection risks among MSM. In contrast, countries such as the United Kingdom initially implemented free HPV vaccination for MSM through sexual health clinics, followed by an expansion of the programme to include adolescent boys. This provides a potentially useful model for Hong Kong to consider. This study aimed to evaluate the cost-effectiveness of implementing 9-valent HPV (9vHPV) vaccination strategies among HIV-positive and HIV-negative MSM in Hong Kong. METHODS: We developed a Markov model to simulate the natural history of HPV infection and progression to genital warts, and anal cancer in a cohort of 100,000 MSM in Hong Kong, stratified by four age groups (12-18, 19-27, 28-45, and > 45 years) and HIV status (positive or negative). A 10-year time horizon was used from the healthcare provider's perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained. One-way and prob...